Accessibility settings

This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (728) Immunology, Allergy, Rheumatology (152) Infectious Diseases (non-STD/STI) (1753) Prevention and Health Promotion (1460) Chronic Conditions (477)

Published on in Vol 14 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/72549, first published .
Optimization of Preemptive Therapy for Cytomegalovirus Infections With Valganciclovir Based on Therapeutic Drug Monitoring: Protocol for a Phase II, Single-Center, Single-Arm Trial

Optimization of Preemptive Therapy for Cytomegalovirus Infections With Valganciclovir Based on Therapeutic Drug Monitoring: Protocol for a Phase II, Single-Center, Single-Arm Trial

Optimization of Preemptive Therapy for Cytomegalovirus Infections With Valganciclovir Based on Therapeutic Drug Monitoring: Protocol for a Phase II, Single-Center, Single-Arm Trial

Authors of this article:

Naoki Tamura1, 2 Author Orcid Image ;   Kotaro Itohara1 Author Orcid Image ;   Yo Ueda3 Author Orcid Image ;   Yumi Kitahiro1 Author Orcid Image ;   Kazuhiro Yamamoto1, 4 Author Orcid Image ;   Tomohiro Omura1 Author Orcid Image ;   Toshiyasu Sakane2 Author Orcid Image ;   Jun Saegusa3 Author Orcid Image ;   Ikuko Yano1 Author Orcid Image
Article Authors Cited by (1) Tweetations Metrics

Journals

  1. Sungur Özgünen M, Tekgöz E, Çolak S, Kılıç Ö, Kaya M, Çınar M, Yılmaz S. Clinical and laboratory features of cytomegalovirus reactivation in immunosuppressed patients with rheumatic diseases. Cukurova Medical Journal 2026;51(1):234 View